Ny strategi vid typ 2-diabetes prövas i kliniska studier. Glukagonlik peptid 1 (GLP-1) påverkar sjukdomens grundorsaker
(2005) In Läkartidningen 102(8). p.9-545- Abstract
- A novel therapy for type 2 diabetes is based on the gut hormone, glucagon-like peptide-1 (GLP-1). GLP-1 is released from the gut during a meal intake and stimulates insulin secretion. The hormone also inhibits glucagon secretion, delays gastric emptying and induces satiety. It has been shown to reduce circulating glucose both under fasting conditions and after meal intake in subjects with type 2 diabetes. A problem in developing this novel therapy is that GLP-1 is rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), which results in a short half-life of the hormone requiring continuous infusion. Two strategies have been developed to circumvent this drawback. One strategy is the use of DPP-4 resistant GLP-1 receptor agonists... (More)
- A novel therapy for type 2 diabetes is based on the gut hormone, glucagon-like peptide-1 (GLP-1). GLP-1 is released from the gut during a meal intake and stimulates insulin secretion. The hormone also inhibits glucagon secretion, delays gastric emptying and induces satiety. It has been shown to reduce circulating glucose both under fasting conditions and after meal intake in subjects with type 2 diabetes. A problem in developing this novel therapy is that GLP-1 is rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), which results in a short half-life of the hormone requiring continuous infusion. Two strategies have been developed to circumvent this drawback. One strategy is the use of DPP-4 resistant GLP-1 receptor agonists (exenatide and liraglutide) and another strategy is to inhibit DPP-4 activity (LAF237). Both these strategies have been successful in clinical studies. (Less)
- Abstract (Swedish)
- GLP-1 (glukagonlik peptid 1) är ett inkretinhormon
som frisätts vid varje måltid.
GLP-1 stimulerar insulinsekretionen, hämmar glukagonsekretionen,
förlångsammar ventrikeltömningen
och ger mättnadskänsla.
Sammantaget har GLP-1 en glukossänkande effekt.
GLP-1 sänker blodglukos och HbA1c när det ges till patienter
med typ 2-diabetes. Risken för hypoglykemi är
mycket liten.
GLP-1 bryts snabbt och effektivt ned av enzymet dipeptidylpeptidas
4 (DPP-4); halveringstiden för hormonet
är <2 minuter.
Två strategier har utvecklats för att kliniskt kunna utnyttja
den goda effekten av GLP-1: dels GLP-1-receptoragonister
som... (More) - GLP-1 (glukagonlik peptid 1) är ett inkretinhormon
som frisätts vid varje måltid.
GLP-1 stimulerar insulinsekretionen, hämmar glukagonsekretionen,
förlångsammar ventrikeltömningen
och ger mättnadskänsla.
Sammantaget har GLP-1 en glukossänkande effekt.
GLP-1 sänker blodglukos och HbA1c när det ges till patienter
med typ 2-diabetes. Risken för hypoglykemi är
mycket liten.
GLP-1 bryts snabbt och effektivt ned av enzymet dipeptidylpeptidas
4 (DPP-4); halveringstiden för hormonet
är <2 minuter.
Två strategier har utvecklats för att kliniskt kunna utnyttja
den goda effekten av GLP-1: dels GLP-1-receptoragonister
som har lång halveringstid genom att
vara resistenta mot DPP-4, dels DPP-4-hämmare som
leder till förlängning av halveringstiden av endogent
frisatt GLP-1.
Substanser utvecklade ur båda dessa strategier är idag
föremål för kliniska studier på fas 3-nivå. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/134811
- author
- Ahrén, Bo LU
- organization
- alternative title
- New strategy in type 2 diabetes tested in clinical trials. Glucagon-like peptide 1 (GLP-1) affects basic caused of the disease
- publishing date
- 2005
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Dipeptidyl Peptidases: antagonists & inhibitors, Type 2: drug therapy, Hypoglycemic Agents: therapeutic use, Humans, Glucagon: therapeutic use, English Abstract, Insulin: cretion, Peptide Fragments: therapeutic use, Protein Precursors: therapeutic use, Receptors, Animals, Biomedical Research, Diabetes Mellitus, Glucagon: tagonists & inhibitors, Research, Serine Proteinase Inhibitors: therapeutic use
- in
- Läkartidningen
- volume
- 102
- issue
- 8
- pages
- 9 - 545
- publisher
- Swedish Medical Association
- external identifiers
-
- pmid:15786905
- scopus:15244358950
- ISSN
- 0023-7205
- language
- Swedish
- LU publication?
- yes
- id
- fa51b848-52ce-445c-9921-45dd4e6917a3 (old id 134811)
- alternative location
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15786905&dopt=Abstract
- http://ltarkiv.lakartidningen.se/artNo29842
- date added to LUP
- 2016-04-01 15:59:38
- date last changed
- 2024-02-26 10:51:45
@article{fa51b848-52ce-445c-9921-45dd4e6917a3,
abstract = {{A novel therapy for type 2 diabetes is based on the gut hormone, glucagon-like peptide-1 (GLP-1). GLP-1 is released from the gut during a meal intake and stimulates insulin secretion. The hormone also inhibits glucagon secretion, delays gastric emptying and induces satiety. It has been shown to reduce circulating glucose both under fasting conditions and after meal intake in subjects with type 2 diabetes. A problem in developing this novel therapy is that GLP-1 is rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), which results in a short half-life of the hormone requiring continuous infusion. Two strategies have been developed to circumvent this drawback. One strategy is the use of DPP-4 resistant GLP-1 receptor agonists (exenatide and liraglutide) and another strategy is to inhibit DPP-4 activity (LAF237). Both these strategies have been successful in clinical studies.}},
author = {{Ahrén, Bo}},
issn = {{0023-7205}},
keywords = {{Dipeptidyl Peptidases: antagonists & inhibitors; Type 2: drug therapy; Hypoglycemic Agents: therapeutic use; Humans; Glucagon: therapeutic use; English Abstract; Insulin: cretion; Peptide Fragments: therapeutic use; Protein Precursors: therapeutic use; Receptors; Animals; Biomedical Research; Diabetes Mellitus; Glucagon: tagonists & inhibitors; Research; Serine Proteinase Inhibitors: therapeutic use}},
language = {{swe}},
number = {{8}},
pages = {{9--545}},
publisher = {{Swedish Medical Association}},
series = {{Läkartidningen}},
title = {{Ny strategi vid typ 2-diabetes prövas i kliniska studier. Glukagonlik peptid 1 (GLP-1) påverkar sjukdomens grundorsaker}},
url = {{http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15786905&dopt=Abstract}},
volume = {{102}},
year = {{2005}},
}